98%
921
2 minutes
20
Members of the genus are notoriously recalcitrant to genetic manipulation due to their extensive and variable repertoire of Restriction-Modification (R-M) systems. Non-replicating plasmids are currently employed to achieve insertional mutagenesis in . One of the limitations of using such insertion vectors is the presence within their sequence of various restriction sites, making them sensitive to the activity of endogenous restriction endonucleases encoded by the target strain. For this reason, vectors have been developed with the aim of methylating and protecting the vector using a methylase-positive strain, in some cases containing a cloned bifidobacterial methylase. Here, we present a mutagenesis approach based on a modified and synthetically produced version of the suicide vector pORI28 (named pFREM28), where all known restriction sites targeted by R-M systems were removed by base substitution (thus preserving the codon usage). After validating the integrity of the erythromycin marker, the vector was successfully employed to target an α-galactosidase gene responsible for raffinose metabolism, an alcohol dehydrogenase gene responsible for mannitol utilization and a gene encoding a priming glycosyltransferase responsible for exopolysaccharides (EPS) production in . The advantage of using this modified approach is the reduction of the amount of time, effort and resources required to generate site-directed mutants in and a similar approach may be employed to target other ( species.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021953 | PMC |
http://dx.doi.org/10.3389/fmicb.2021.636822 | DOI Listing |
Mol Ther
September 2025
The Ohio State University James Comprehensive Cancer Center, Columbus, OH 43210, USA.
A Chimeric Antigen Receptor (CAR) positive CD30+/CD4+ T-cell lymphoma (TCL) manifested as a single oral ulceration 22 months after treatment with tisagenlecleucel (tisa-cel), an anti-CD19 CAR T-cell based therapy. TCL showed lentiviral integration in ANKHD1-EIF4EBP3, loss of function of TET2, and NTRK1 copy number gain, suggesting that genetic alterations unrelated to insertional mutagenesis contributed to lymphomagenesis. The patient remains in remission two years after radiotherapy.
View Article and Find Full Text PDFHum Mutat
September 2025
Department of Dermatology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Dyskeratosis congenita (DC) is an inherited bone marrow failure syndrome characterized by defects in telomere biology and clinical manifestations such as nail dystrophy, skin pigmentation abnormalities, and mucosal leukoplakia. Here, using whole exome sequencing (WES), whole genome sequencing (WGS), optical mapping sequencing (OGM), third-generation sequencing, and mRNA sequencing, we diagnosed a participant with gene complex compound heterozygous variants. In addition, protein structure simulation, immunohistochemistry, and western blot were conducted to investigate the structure and expression level of the PARN protein.
View Article and Find Full Text PDFHum Gene Ther
September 2025
GENYO, Centre for Genomics and Oncological Research: Pfizer, Andalusian Regional Government PTS Granada, University of Granada, Granada, Spain.
Seven cases of hematological malignancy reported in recipients of Skysona™ (elivaldogene autotemcel) have reignited long-standing concerns about insertional mutagenesis in lentiviral vector (LV)-based gene therapy. Here, we dissect the molecular and clinical evidence underlying these events, place them in the broader context of over 300 patients treated with LV-modified hematopoietic stem and progenitor cells (HSPCs), and review the real-world safety record of LV-engineered chimeric antigen receptor T cells. We show that cancers associated with Skysona are mechanistically linked to the use of a potent viral MNDU3 promoter probably combined with intensive conditioning and growth-factor support, whereas LV products employing weak or physiological promoters continue to display an excellent safety profile.
View Article and Find Full Text PDFChem Asian J
August 2025
Department of Anesthesiology, Department of Otolaryngology Head and Neck Surgery, Second Affiliated Hospital of Air Force Medical University, Xi'an, 710038, P. R. China.
Gene therapy holds immense potential for treating genetic disorders, malignancies, and infectious diseases through the targeted introduction, silencing, or precise editing of therapeutic genes. Although viral vectors exhibit exceptionally high gene transfection efficiency, their clinical application faces significant challenges, including robust immunogenicity, the insertional mutagenesis risks, complex and costly manufacturing processes hindering large-scale manufacturing, limited gene cargo capacity, and poor packaging efficiency for large genes. In contrast, nonviral vectors-such as lipid nanoparticles (LNPs), cationic polymers, and inorganic nanoparticles, offer numerous advantages, including superior safety profiles, the scalability for manufacturing, structural and functional reconfigurability in accommodating various sizes cargo.
View Article and Find Full Text PDFNat Commun
August 2025
Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Gene and cell therapies pose safety concerns due to potential insertional mutagenesis by viral vectors. We introduce MELISSA, a regression-based statistical framework for analyzing Integration Site (IS) data to assess insertional mutagenesis risk, by estimating and comparing gene-specific integration rates and their impact on clone fitness. We characterized the IS profile of a lentiviral vector on Mesenchymal Stem Cells (MSCs) and compared it with that of Hematopoietic Stem and Progenitor Cells (HSPCs).
View Article and Find Full Text PDF